Skip to content
For US Healthcare Professionals Patient Site
Picture of LEMTRADA patient Kim. Picture of LEMTRADA patient Kim.
Kim
44
Magnolia, TX
married, mother of 3, pre-school teacher
“I live an active life, and my disease progression made caring for my 3 children increasingly difficult.”

DISEASE HISTORY

20 Years

since RMS diagnosis

PATIENT BACKGROUND

RMS Risk Factors

African American, incomplete recovery from relapse

RMS TREATMENT HISTORY

2 prior DMTs:
1 injectable and
1 oral therapy

WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

I was having multiple relapses and I was determined to find another treatment option. My HCP team agreed to discuss options and see what to do next.

WHY LEMTRADA?

After reviewing both the safety and efficacy data with my doctor, my family and I felt the potential benefits outweighed the risks for me. The required monthly monitoring and self-checks would allow me and my HCP to keep an eye on my health. And if getting to my HCP or lab was too difficult, I knew that I could have a visiting lab technician come to my home.

DID YOU HAVE ANY CONCERNS ABOUT STARTING LEMTRADA?

Potential autoimmune side effects were my greatest concern. As a result of one of my regular self-checks, I discovered a blister in my mouth and I contacted my doctor immediately. He told me it was ITP, or immune thrombocytopenic purpura, which meant that I had low blood platelet levels.

WHAT WOULD YOU TELL SOMEONE ABOUT YOUR EXPERIENCE?

I’m at the end of my scheduled monitoring since taking LEMTRADA 5 years ago. The ITP was treated, I’ve had no relapses, and my doctor hasn’t seen any signs of disability progression. I'm glad I learned more about LEMTRADA and was able to make an informed decision. In the future, if my doctor thinks I need an additional course of treatment and monitoring, I will do it again.

Are your patients interested in learning
more about LEMTRADA?

Download the full patient resource

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text